ProMIS Neurosciences announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for PMN310 for the treatment of AD.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PMN:
- ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310
- Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023
- ProMIS Neurosciences presents in vitro preclinical data on PMN310
- ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting
- ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023